Stress Cardiac MRI in Ischemic Patients

Assessment of Myocardial Viability by Cardiac Magnetic Resonance Feature Tracking at Rest and During Stress by Low Dose Dobutamine

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04588675

Enrollment

Registered

2020-10-19

Start date

2021-11-30

Completion date

2022-06-30

Last updated

2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Cardiomyopathy

Brief summary

The aim of this study is to assess the diagnostic accuracy of CMR feature-tracking (FT) at rest & during stress with low dose dobutamine (LDD) in the evaluation of viability in ischemic cardiomyopathy (ICM) patients and compare it with delayed gadolinium enhancement (DGE).

Interventions

DIAGNOSTIC_TESTMRI

the patients will underwent dobutamine stress cardiac MRI

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* All patients recruited into the study have chronic LV systolic dysfunction due to coronary artery disease (CAD)

Exclusion criteria

* All patients with a contraindication to MR study: * Patients with implanted non-MRI compatible electronic devices (e.g. Cardiac pacemakers, intracranial metallic clips, implanted hearing aids, etc.) * Patients with foreign bodies in the eye. * Claustrophobic patients. * Patients diagnosed with recent acute coronary syndrome within 4 weeks. * Patients who had contraindications for MRI or contrast agents, and those with poor image quality due to either inadequate breath holding or arrhythmias

Design outcomes

Primary

Measure	Time frame	Description
comparison of myocardial strain with late gadolinium enhancement	Baseline	analysis of the myocardial strain by low dose dobutamine and test if it can assess myocardial viability

Contacts

Primary ContactAbdulrahman Hamdan

abdulrahman.emam@med.au.edu.eg1005363950

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026